FeesSafety
Pluang+

Vaso reports Q3 2026 net income of $568K on $10.8M revenue, down from last year amid business divestitures.

Company Fundamentals
16 Nov 2026, 16:00 WIB
GlobeNewsWire
View Source
Neutral
Vaso reports Q3 2026 net income of $568K on $10.8M revenue, down from last year amid business divestitures.

Vaso Corporation announced its Q3 2026 financial results with net income of $568,000 on $10.8 million revenue, down from $1.7 million net income and $11.4 million revenue in the same quarter last year. The decline is mainly due to divestitures of its healthcare IT and network services businesses completed in late 2025 and mid-2026. Despite lower revenue, the company expects improved efficiency and profitability by focusing on its professional sales services and proprietary medical device segments. Cash from operations was $6.5 million for the first nine months of 2026, and deferred revenue increased by 5.4% year-over-year.

Vaso Corporation's financial results for Q3 2026 show a net income of $568,000, down from $1.7 million the previous year, reflecting its strategic divestitures. For readers following the health sector, here is Pluang's market snapshot as of Nov 16, 2026 20:15 WIB: out of 150 priced health-sector US stocks, 73 rose and 60 fell today. Notable movers include AHCO at USD 7.42 with a 3.13% decline, BNGO rising 3.00% to USD 1.03, and IBRX down 2.82% at USD 5.85, with typical hold times ranging from 4 to 52 days on Pluang.

More News

Walk assist robot market to grow 15% CAGR by 2031, driven by AI, aging population, and stroke rehab demand

Walk assist robot market to grow 15% CAGR by 2031, driven by AI, aging population, and stroke rehab demand

The global walk assist robot market is projected to grow at a 15.01% CAGR from 2024 to 2031, fueled by advances in AI, machine learning, and hybrid wearable technology. Rising stroke incidence and an aging population are increasing demand for these r...

Market News
Bullish
1 hour ago
Anti-obesity drug market to hit $64.96B by 2035, led by Eli Lilly and Novo Nordisk with strong new drug launches.

Anti-obesity drug market to hit $64.96B by 2035, led by Eli Lilly and Novo Nordisk with strong new drug launches.

The global anti-obesity drugs market is projected to grow from USD 8.96 billion in 2026 to USD 64.96 billion by 2035, driven by a CAGR of 24.71%. Eli Lilly and Novo Nordisk dominate the market with blockbuster drugs like Mounjaro, Zepbound, and Wegov...

Bullish
1 hour ago
Sandisk announces 8-for-1 stock split effective Nov 19, focusing on flash memory prices over share count.

Sandisk announces 8-for-1 stock split effective Nov 19, focusing on flash memory prices over share count.

Sandisk will execute an 8-for-1 stock split on November 19, 2026, increasing the number of shares outstanding while reducing the price per share. Despite this split, the company emphasizes that flash memory prices remain the key factor influencing it...

Company Fundamentals
Neutral
1 hour ago
Nike faces scrutiny over cost-cutting ahead of first investor day since 2017

Nike faces scrutiny over cost-cutting ahead of first investor day since 2017

Nike is under pressure to clarify its cost-cutting plans as it prepares for its first investor day since 2017, scheduled for November 16–17. Despite efforts led by CEO Elliott Hill to turn the company around, management expects revenue to decline by ...

Market News
Bearish
1 hour ago
Jackery and Every Electric launch North America's first plug-in virtual power plant for renters in NYC.

Jackery and Every Electric launch North America's first plug-in virtual power plant for renters in NYC.

Jackery and Every Electric have partnered to create North America's first plug-and-play virtual power plant (VPP) for renters and apartment residents, starting in New York City. This innovative system uses portable power stations plugged into standar...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App